We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ProBioGen and Emergent BioSolutions Partner
News

ProBioGen and Emergent BioSolutions Partner

ProBioGen and Emergent BioSolutions Partner
News

ProBioGen and Emergent BioSolutions Partner

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ProBioGen and Emergent BioSolutions Partner"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ProBioGen announced that it has signed an agreement with Emergent BioSolutions for a non-exclusive commercial multi-product license and option agreement under which Emergent will be granted broad access to ProBioGen’s avian AGE1.CR® cell line.

Previously, ProBioGen had granted an exclusive license to Emergent for four indications and also conducted process development work for Emergent. As a result of the new agreement, ProBioGen’s relationship with Emergent is now extended to include additional infectious disease targets, with the option to expand to numerous further indications. The commercial licenses include milestones and royalty payments. Financial details were not disclosed.

Volker Sandig, Chief Scientific Officer noted: “Innovative medicines against infectious diseases are urgently needed. We are convinced that the combination of ProBioGen’s AGE1.CR® cell line for production of MVA-based vaccines together with Emergent’s product development, manufacturing and marketing expertise will yield novel preventive and therapeutic products."

Advertisement